Focal therapy cuts prostate cancer side effects. Discover the promising 10-year results and why NHS access remains limited.

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a ...

177Lu-PSMA-I&T therapy improved radiographic progression-free survival in metastatic castration-resistant prostate cancer patients. The ECLIPSE trial compared 177Lu-PSMA-I&T with hormone therapy, ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Doctors reported a rare complete response in a patient with advanced prostate cancer following targeted radioactive treatment ...

In a new study led by the UCLA Health Jonsson Comprehensive Cancer Center, investigators show that using advanced MRI imaging and targeted focal therapy can help many men with low- to ...

A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports. The ‘search and destroy’ treatment shrank ...

Upfront PSMA PET imaging detects hidden metastases in early prostate cancer, altering treatment plans in up to one-third of ...

SINGAPORE—For decades, brachytherapy has been a mainstay in cancer treatment, offering highly targeted radiation for patients with cervical and other gynecological cancers, prostate cancer, breast ...